Therapeutic Asset Ratings

141 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Dimethyloxobuthylphosphonilmethylate Stroke	Tatchempharmpreparaty, JSC	P3	CCC (52)
dl-3-butylphthalide Stroke	Fudan University	P3	CCC (52)
Nono-42 Stroke	The George Institute	P3	CCC (52)
Recaticimab Stroke	Shanghai East Hospital	P3	CCC (52)
Metformin Stroke	Spaulding Rehabilitation Hospital	P2	CCC (52)
HEPARIN Stroke	Kastamonu University	P3	CCC (51)
Modafinil Stroke	University Health Network, Toronto	P3	CCC (51)
Byetta Stroke	Christina Kruuse	P2	CCC (51)
UROKINASE-TYPE PLASMINOGEN ACTIVATOR Stroke	Huashan Hospital	P2	CCC (51)
M-SYMPATHOL Stroke	Zhejiang Cancer Hospital	P3	CCC (50)
RAMIPRIL Stroke	Northern California Institute of Research and Education	P3	CCC (50)
Phenobarbital Stroke	University of North Carolina, Chapel Hill	P4	CCC (49)
Abelacimab Stroke	Anthos Therapeutics, Inc.	P2	CCC (48)
Ceftriaxone Stroke	Tianjin Medical University General Hospital	P2	CCC (48)
Deferiprone Stroke	University Hospital, Bordeaux	P2	CCC (48)
Drf Stroke	University Hospital, Lille	P2	CCC (48)
Hyaluronidase Stroke	Johns Hopkins University	P2	CCC (48)
Inomax Stroke	Steven Messe	P2	CCC (48)
MANNITOL Stroke	Emmanuel Carrera	P2	CCC (48)
Sinemet Pill Stroke	University of California, Los Angeles	P1/2	CC (44)
Allogeneic Umbilical Cord Blood Stroke	The Medical Pavilion Bahamas	P1	CC (43)
HUMAN RELAXIN 1 Stroke	Deeptankar DeMazumder	P1/2	CC (41)
Infliximab Stroke	University of California, San Francisco	P1/2	CC (41)
Mtr-601 Stroke	Motric Bio	P1	CC (40)
Alloex Stroke	The Foundation for Orthopaedics and Regenerative Medicine	P1	C (37)

Showing 76 to 100 of 141 assets